期刊
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY
卷 26, 期 4, 页码 471-485出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.bpg.2012.09.008
关键词
Hepatitis C virus; Direct acting antiviral agents; NS3/4A protease inhibitor; NS5A; NS5B; Nucleotide inhibitors; Non-nucleotide inhibitors; Cyclophilin inhibitor
资金
- Roche
- Merck
- BI
- BMS
- Gilead
- Novartis
- Abbott
- Idenix
- National Institutes of Health Research (NIHR) [DRF-2010-03-29] Funding Source: National Institutes of Health Research (NIHR)
- National Institute for Health Research [DRF-2010-03-29] Funding Source: researchfish
Treatment for those infected with chronic hepatitis C virus [HCV] has until recently been hampered by the lack of therapies other than pegylated interferon and ribavirin, which have limited efficacy and a difficult side effect profile. To address this, multiple new direct acting antiviral drugs which specifically target the nonstructural proteins involved in HCV replication are in phase II/III development. This review will discuss the HCV replication cycle, mechanisms of action of the new direct acting antiviral drugs, results from published trials into their efficacy and the potential for interferon free treatment regimens in the future. (C) 2012 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据